Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...
3d
Pharmaceutical Technology on MSNSupernus’s stock sinks after depression drug fails trialThe company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
The U.S. has a much higher rate of maternal mortality than other high-income countries, and the risks are especially acute ...
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
Hosted on MSN27d
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatmentThe Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever stand-alone therapy for treatment-resistant depression, which is when trying at least two standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results